Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway

Abstract

Resistance of tumors to cytotoxic therapy may be due to disrupted apoptosis programs and remains a major obstacle in cancer treatment. Here, we report that IFNγ sensitizes resistant tumor cells with absent or low caspase-8 expression for apoptosis induced by death-inducing ligands or cytotoxic drugs by upregulating caspase-8 through a Stat1/IRF1 dependent pathway. Combined treatment using IFNγ with TRAIL, APO1, TNFα or cytotoxic drugs cooperated to trigger apoptosis in various resistant tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, while single agents exerted only a minimal effect. Importantly, IFNγ induced caspase-8 expression also in cells with inactivation of the caspase-8 gene by hypermethylation, although no direct effect of IFNγ on the methylation status of regulatory sequences of the caspase-8 gene was found. IFNγ-mediated facilitation of apoptosis was inhibited by the caspase-8 specific inhibitor zIETD.fmk or in caspase-8 mutant Jurkat cells implying a prominent role of caspase-8 in mediating sensitization by IFNγ. Upregulation of caspase-8 and sensitization for apoptosis by IFNγ was blocked by overexpression of dominant-negative mutants of Stat1 or in Stat1-deficient U3A cells, while complementation of Stat1-deficient U3A cells with wild-type Stat1 restored the IFNγ effect. Moreover, ectopic expression of IRF1 induced caspase-8 expression thereby sensitizing cells for TRAIL-, APO1- or doxorubicin-induced apoptosis. These findings provide evidence that the Stat1/IRF1 pathway is involved in induction of caspase-8 expression and apoptosis initiated by IFNγ and indicate that IFNγ might be an effective strategy to sensitize various resistant tumor cells with deficient caspase-8 expression for chemotherapy- or death receptor-induced apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Boehm U, Klamp T, Groot M, Howard JC . 1997 Ann. Rev. Immunol. 15: 749–795

  • Bromberg J, Darnell Jr JE . 2000 Oncogene 19: 2468–2473

  • Darnell Jr JE, Kerr IM, Stark GR . 1994 Science 264: 1415–1421

  • Debatin KM . 1997 J. Natl. Cancer Inst. 89: 750–751

  • Deveraux QL, Reed JC . 1999 Genes Dev. 13: 239–252

  • Friesen C, Herr I, Krammer PH, Debatin KM . 1996 Nat. Med. 2: 574–577

  • Friesen C, Fulda S, Debatin KM . 1997 Leukemia 11: 1833–1841

  • Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . 1997 Cancer Res. 57: 3823–3829

  • Fulda S, Susin SA, Kroemer G, Debatin KM . 1998 Cancer Res. 58: 4453–4460

  • Fulda S, Meyer E, Debatin KM . 2000 Cancer Res. 60: 3947–3956

  • Fulda S, Küfer M, van Valen F, Dockhorn-Dworniczak B, Debatin KM . 2001 Oncogene 20: 5865–5877

  • Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ . 1999 Gene 226: 225–232

  • Griffith TS, Lynch DH . 1998 Curr. Opin. Immunol. 10: 559–563

  • Hendrich B, Bird A . 2000 Curr. Top. Microbiol. Immunol. 249: 55–74

  • Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Herman JG, Baylin SB . 2000 Curr. Top. Microbiol. Immunol. 249: 35–54

  • Iwase S, Furukawa Y, Kikuchi J, Saito S, Nakamura M, Nakayama R, Horiguchi-Yamada J, Yamada H . 1999 FEBS Lett. 450: 263–267

  • Jones PA . 1985 Cell 40: 485–486

  • Juo P, Kuo CJ, Yuan J, Blenis J . 1998 Curr. Biol. 8: 1001–1008

  • Kaufmann SH, Earnshaw WC . 2000 Exp. Cell Res. 256: 42–49

  • Kroemer G . 1997 Nat. Med. 3: 614–620

  • Kroemer G, Reed JC . 2000 Nat. Med. 6: 513–519

  • Los M, Wesselborg S, Schulze-Osthoff K . 1999 Immunity 10: 629–639

  • Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M . 1998 Oncogene 17: 339–346

  • Maris JM, Matthay KK . 1999 J. Clin. Onco. 17: 2264–2279

  • McKendry R, John J, Flavell D, Muller M, Kerr IM, Stark GR . 1991 Proc. Natl. Acad. Sci. USA 88: 11455–11459

  • Montaldo PG, Carbone R, Corrias MV, Ferraris PC, Ponzoni M . 1994 J. Natl. Cancer Inst. 86: 1694–1701

  • Nicholson DW . 1999 Cell Death Differ. 6: 1028–1042

  • Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC . 1997 J. Biol. Chem. 272: 16351–16357

  • Peter ME, Krammer PH . 1998 Curr. Opin. Immunol. 10: 545–551

  • Rountree MR, Bachman KE, Herman JG, Baylin SB . 2001 Oncogene 20: 3156–3165

  • Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A . 2000 Cancer Res. 60: 5673–5680

  • Salvesen GS, Dixit VM . 1999 Proc. Natl. Acad. Sci. USA 6: 10964–10967

  • Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958

  • Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . 2000 Immunity 12: 599–609

  • Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD . 1998 Ann. Rev. Biochem. 67: 227–264

  • Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G . 1999 Nature 397: 441–446

  • Tang D, Lahti JM, Kidd VJ . 2000 J. Biol. Chem. 275: 9303–9307

  • Taniguchi T, Lamphier MS, Tanaka N . 1997 Biochim. Biophys. Acta 1333: M9–M17

  • Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ . 2000 Nat. Med. 6: 529–535

  • Thornberry N, Lazebnik Y . 1998 Science 281: 1312–1316

  • Tschopp J, Irmler M, Thome M . 1998 Curr. Opin. Immunol. 10: 552–558

  • Van Valen F . 1999 Ewing's Sarcoma Family of Tumors Masters JRW and Palsson B (eds) Great Britain: Kluwer Academic Publishers pp 55–85

    Google Scholar 

  • Wadler S, Schwartz EL . 1990 Cancer Res. 50: 3473–3486

Download references

Acknowledgements

We thank Petra Miller-Rostek for expert technical assistance, PH Krammer (DKFZ, Heidelberg, Germany) for anti-FLICE antibody, JF Bromberg (The Rockefeller University, New York, USA) for pRcCMV plasmid containing Stat1 Y701F or Stat1β cDNA, S Iwase (Aoto Hospital, Tokyo, Japan) for pCR3.1 plasmid containing IRF1 cDNA, GR Stark (The Cleveland Clinic Foundation, Cleveland, USA) for 2fTGH, U3A and U3AStat1 cells and J Blenis (Harvard Medical School, Boston, USA) for caspase-8 mutant Jurkat cells. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung and Technologie, Bonn, the Deutsche Leukämieforschungshilfe and the Wilhelm Sander-Stiftung.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Klaus-Michael Debatin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fulda, S., Debatin, KM. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21, 2295–2308 (2002). https://doi.org/10.1038/sj.onc.1205255

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205255

Keywords

This article is cited by

Search

Quick links